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Comparison of AngioJet Rheolytic
Thrombectomy Before Direct Infarct
Artery Stenting With Direct Stenting Alone
in Patients With Acute Myocardial Infarction
The JETSTENT Trial
Angela Migliorini, MD,* Amerigo Stabile, MD,† Alfredo E. Rodriguez, MD, PHD,‡
Caterina Gandolfo, MD,† Alfredo M. Rodriguez Granillo, MD,‡ Renato Valenti, MD,*
Guido Parodi, MD, PHD,* Franz-Josef Neumann, MD,§ Antonio Colombo, MD,¶
David Antoniucci, MD,* on behalf of the JETSTENT Trial Investigators
Florence, Palermo, and Milan, Italy; Buenos Aires, Argentina; and Bad Krozingen, Germany
Objectives The aim of this study was to determine whether rheolytic thrombectomy (RT) before direct infarct artery stenting
as compared with direct stenting (DS) alone results in improved myocardial reperfusion and clinical outcome in
patients with acute myocardial infarction.
Background The routine removal of thrombus before infarct artery stenting is still a matter of debate.
Methods This is a multicenter, international, randomized, 2-arm, prospective study. Eligible patients were patients
with acute myocardial infarction, angiographic evidence of thrombus grade 3 to 5, and a reference vessel
diameter 2.5 mm. Coprimary end points were early ST-segment resolution and 99mTc-sestamibi infarct
size. An  value  0.05 achieved by both coprimary surrogate end points or an  value  0.025 for a sin-
gle primary surrogate end point would be considered evidence of statistical significance. Other surrogate
end points were Thrombolysis In Myocardial Infarction (TIMI) flow grade 3, corrected TIMI frame count, and
TIMI grade 3 blush. Clinical end points were a composite of major adverse cardiovascular events at 1, 6,
and 12 months.
Results From December 2005 to September 2009, 501 patients were randomly allocated to RT before DS or to DS
alone. The ST-segment resolution was more frequent in the RT arm as compared with the DS alone arm: 85.8%
and 78.8%, respectively (p  0.043), while no difference between groups were revealed in the other surrogate
end points. The 6-month major adverse cardiovascular events rate was 11.2% in the thrombectomy arm and
19.4% in the DS alone arm (p  0.011). The 1-year event-free survival rates were 85.2  2.3% for the RT arm,
and 75.0  3.1% for the DS alone arm (p  0.009).
Conclusions Although the primary efficacy end points were not met, the results of this study support the use of RT before
infarct artery stenting in patients with acute myocardial infarction and evidence of coronary thrombus. (AngioJet
Rheolytic Thrombectomy Before Direct Infarct Artery Stenting in Patients Undergoing Primary PCI for Acute Myo-
cardial Infarction [JETSTENT]; NCT00275990) (J Am Coll Cardiol 2010;56:1298–306) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.011c
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tcclusive thrombus complicating a ruptured or eroded
therosclerotic plaque is the most frequent pathologic sub-
trate of acute myocardial infarction (AMI). Primary per-
rom the *Careggi Hospital, Florence, Italy; †Ospedale Civico, Palermo, Italy;
Otamendi Hospital, Buenos Aires, Argentina; §Herz-Zentrum Bad Krozingen, Bad
rozingen, Germany; and the ¶Columbus Hospital, Milan, Italy. All authors have
eported that they have no relationships to disclose.d
Manuscript received March 21, 2010; revised manuscript received June 1, 2010,
ccepted June 6, 2010.utaneous intervention (PCI) for AMI may be complicated
y distal atherothrombotic embolization, with resulting
icrovessel network disruption and failed myocardial reper-
See page 1307
usion. Several primary PCI randomized studies assessing
he efficacy of embolic protection devices or thrombectomy
evices in improving myocardial reperfusion, and meta-
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October 12, 2010:1298–306 Rheolytic Thrombectomynalyses derived from these studies have produced negative
r conflicting results (1–5). Moreover, most studies did not
how any clinical benefit of thrombectomy, and the indica-
ion for routine removal of thrombus before infarct artery
tenting is still matter of debate.
Most of the concluded randomized trials used manual
spiration catheters, whereas only 2 studies used the rheo-
ytic thrombectomy (RT) device, producing conflicting
esults (6,7).
The aim of this study was to determine whether RT
efore direct infarct artery stenting as compared with direct
tenting (DS) alone results in improved myocardial reper-
usion and clinical outcome in patients with AMI.
ethods
tudy design. The comparison of the JETSTENT
AngioJet Rheolytic Thrombectomy Before Direct Infarct
rtery Stenting With Direct Stenting Alone in Patients
ith Acute Myocardial Infarction) trial is a multicenter,
nternational, randomized, 2-arm, prospective study (On-
ine Appendix). The study is registered with ClinicalTrials.
ov (NCT00275990). The trial was designed by the principal
nvestigators and sponsored by Medrad Interventional/Possis
Minneapolis, Minnesota). Other than providing financial
upport and thrombectomy devices the sponsor was not in-
olved in the management, collection, or analysis of data.
atients. All patients with ST-segment elevation AMI
ere considered eligible for the study without restriction
ased on age or clinical status on presentation. Thus,
atients with cardiogenic shock were eligible for the study.
he diagnosis of AMI: 1) chest pain persisting 30 min
Figure 1 Randomization Flow
cTFC  corrected TIMI frame count; MACE  major adverse cardiovascular eventsnd 12 h; and 2) ST-segment
levation 1 mm in at least 2
ontiguous leads or presumably
ew left bundle branch block.
linical exclusion criteria were:
) thrombolysis for current AMI;
) major surgery 6 weeks; 3)
troke30 days or any history of
emorrhagic stroke; 4) comor-
idities with expected survival
1 year; and 5) participation in
nother study.
The study was approved by the
nstitutional ethics committee at
ach participating center, and
atients signed written informed consent.
andomization. Randomization to RT before DS or DS
lone was performed after coronary angiography and wiring
f the infarct artery (Fig. 1). The TIMI (Thrombolysis In
yocardial Infarction) study thrombus score was used for
he assessment of thrombus dimensions (8). Patients with
ngiographic evidence of TIMI thrombus grades 3 to 5 after
nfarct artery wiring could be randomized if the reference
iameter of the infarct artery was 2.5 mm on visual
ssessment. Angiographic criteria for exclusion from
andomization included: 1) TIMI thrombus grade 3;
) infarct artery reference diameter 2.5 mm on visual
ssessment; 3) previous stenting of the infarct artery; and
) inability to identify the infarct artery. Evidence of
assive coronary thrombus, diffuse disease, a major
ranch involved in the culprit lesion, calcification, left
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
IQR  interquartile range
MACE  major adverse
cardiovascular events
PCI  percutaneous
coronary intervention
STR  ST-segment
elevation resolution
TIMI  Thrombolysis In
Myocardial Infarction
 Thrombolysis In Myocardial Infarction.; TIMI
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Rheolytic Thrombectomy October 12, 2010:1298–306ain disease, or severe vessel tortuosity were not angio-
raphic exclusion criteria. Randomization was carried out
y computer-generated sequence, and assignments were
rovided by a centralized telephone system.
heolytic thrombectomy. The AngioJet rheolytic throm-
ectomy system (Medrad Interventional/Possis, Minneap-
lis, Minnesota) consists of a drive unit console, a disposable
ump set, and a 4-F disposable catheter. Thrombectomy is
ccomplished with high-velocity saline jets contained within
he distal catheter tip. These jets create a strong negative
ressure (Bernoulli effect) that entrains the thrombus to the
atheter inflow windows, where it is captured, fragmented, and
vacuated from the body through the catheter and associated
ubing. The single-pass anterograde thrombectomy technique
as used. This technique includes: 1) catheter activation at
east 1 cm proximal to the thrombus, to create a suction
ortex before advancing the device; 2) advancing the throm-
ectomy catheter slowly (1 to 3 mm/s) to and through the
hrombosed segment; and 3) restarting the thrombectomy at
he end of the proximal-to-distal pass, with a distal-to-
roximal pullback. After the first pass, the device was
etrieved into the guide catheter, and an angiographic check
as performed to assess restoration of TIMI flow. If a
IMI flow grade 2 or 3 was restored and there was no more
vidence of residual thrombus, thrombectomy treatment
as stopped, whereas a second or third pass could be made
f there was evidence of residual thrombus or a TIMI flow
rade 2.
nfarct artery stenting. In both arms, DS was attempted in
ll cases using bare-metal stents. The stent type choice was
t the operator’s discretion. If the stent failed to directly
ross the lesion, pre-dilation was performed using an un-
ersized balloon to decrease the risk of embolism before
tent implantation. Pressure deployment and expansion
ere at the discretion of the operator according to the
haracteristics of the stent and lesion.
djunctive treatments. Patients received 325 mg of aspi-
in orally, or 250 mg intravenously at the emergency room,
nd a loading dose of 600 mg of clopidogrel before or
mmediately after the procedure. All patients received ab-
iximab (ReoPro, Centocor, Malvern, Pennsylvania) unless
ontraindicated. Abciximab was administered immediately
efore or during the procedure as a bolus of 0.25 mg/kg
ody weight followed by a 12-h infusion at a rate of
.125 g/kg/min. Heparin was given as an initial bolus of
0 U/kg, and additional boluses were administered during
he procedure to achieve an activated clotting time of 200 to
50 s. After the procedure, patients were treated with
spirin (100 to 325 mg daily indefinitely) and clopidogrel
75 mg daily for 6 months). Other drugs such as beta-
lockers, angiotensin-converting enzyme inhibitors, and
tatins were used in accordance with standard and recom-
ended practice.
ultivessel intervention. Multivessel intervention was al-owed only in patients with cardiogenic shock; otherwise, brocedures in noninfarct arteries were performed after the
-month scintigraphy.
ollow-up. All patients were scheduled for clinical
ollow-up at 1, 6, and 12 months. All other possible
nformation derived from hospital readmission or from the
eferring physician, relatives, or municipality live registries
ere entered into the prospective database. The treatment
rotocol did not include angiographic follow-up. Unsched-
led angiography was allowed on the basis of clinical
ndication.
nd points. The study was designed to test the hypothesis
hat RT before DS will result in improved myocardial
eperfusion, increased myocardial salvage, decreased infarct
ize, and better clinical outcome. Moreover, the removal of
hrombus allowing a better estimate of the diameter and
ength of the target lesion may result in the use of stents
ith the most appropriate size.
Surrogate coprimary end points of the study are ST-
egment elevation resolution (STR) at 30 min after PCI,
nd infarct size as assessed by 99mTc sestamibi scintigraphy
t 1 month.
Baseline and 30-min post-procedure, a 12-lead electro-
ardiogram was recorded using the same electrocardiograph.
he ST-segment changes were evaluated in the single lead
ith the most prominent ST-segment elevation before
echanical intervention. The ST-segment elevation was
easured to the nearest 0.5 mm at 60 ms after the J point
ith the aid of hand-held calipers. The STR was defined as
reduction in ST-segment elevation 50% at 30 min after
nfarct artery recanalization (9). The STR was assessed by
hysicians blinded to treatment assignment at a central core
aboratory.
All eligible patients underwent electrocardiography-gated
ingle-positron emission computed tomography imaging
ith 99mTc sestamibi at 1 month (30  10 days) after the
ndex procedure. Raw patient data were processed by a
hysician blinded to treatment assignment at a central core
aboratory. Infarct size was expressed as percentage involve-
ent of the left ventricle (10). Patients who died before the
cheduled scintigraphy had an imputed infarct size equal to
he 75th percentile for the treatment arm.
Other surrogate secondary end points include: 1) post-
CI TIMI flow grade 3; 2) corrected TIMI frame count;
nd 3) TIMI blush grade 3 (11–13). All angiographic
arkers of reperfusion and quantitative coronary angiogra-
hy analysis were performed at central core laboratory by
hysicians not involved in the study.
Key secondary clinical end points are the 1-, 6-, and
2-month composite of major adverse cardiovascular events
MACE) including death, myocardial infarction, target
essel revascularization, and stroke.
Reinfarction was defined as recurrent chest pain with
T-segment or T-wave changes and recurrent elevation of
ardiac enzymes. Target vessel revascularization was defined
s coronary angioplasty or coronary surgery performed
ecause of restenosis or reocclusion of the infarct artery.
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October 12, 2010:1298–306 Rheolytic Thrombectomytroke was defined as an acute neurological defect lasting
24 h. Major bleeding was defined according to the TIMI
riteria (14).
All clinical events were adjudicated by an independent
linical event committee blinded to treatment allocation
fter review of original source documentation.
tatistical methods. Based on the results of a previous
tudy (6), the study was powered to demonstrate an increase
n STR from an expected 70% in the DS alone group to
0% in the RT arm, and a 30% relative reduction infarct size
ith RT, assuming a 16% infarct size with standard devia-
ion of 14% in the control arm. An  value  0.05 achieved
y both coprimary surrogate end points or an  value 
.025 for a single primary surrogate end point would be
onsidered evidence of statistical significance. The statistical
ower is 95%, based on a maximum sample size of 500
atients (with 450 evaluable patients) randomized in a 1:1
aseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Rheolytic
Thrombectomy
(n  256)
Direct
Stenting
(n  245) p Value
Age, yrs 63.0 12.3 64.3 11.5 0.208
Range 24–94 34–91
Male sex 195 (76) 199 (81) 0.168
Hypertension 120 (47) 116 (47) 0.916
Dyslipidemia 77 (30) 85 (35) 0.270
Diabetes mellitus 36 (14) 37 (15) 0.742
Previous myocardial infarction 10 (3.9) 12 (4.9) 0.588
Anterior myocardial infarction 101 (39) 91 (37) 0.595
Cardiogenic shock 7 (2.7) 13 (5.3) 0.142
Previous PCI 11 (4.3) 10 (4.1) 0.904
Previous CABG 1 (0.4) 1 (0.4) 0.975
Symptoms to admission, min 125 (85–221) 135 (86–227) 0.853
ST-segment elevation, mm 3.98 2.49 4.02 2.69 0.886
alues are mean  SD, n (%), or median (interquartile range).
CABG  coronary artery bypass graft; IQR  interquartile range; PCI  percutaneous coronary
ntervention.
Baseline Angiographic CharacteristicsTable 2 Baseline Angiographic Characterist
Rheolytic Th
(n 
Infarct artery
Left anterior descending artery 107 (42
Right coronary artery 112 (44
Circumflex arter 37 (14
Reference vessel diameter, mm 2.94 (2.
Multivessel disease 114 (44
Pre-wiring TIMI flow grade 0–1 212/25
Post-wiring TIMI flow grade 0–1 142/23
TIMI thrombus grade post-wiring (%)
1–2 3 (1.
3 73 (32
4 83 (37
5 63 (28Values are n (%) or median (interquartile range).
TIMI  Thrombolysis In Myocardial Infarction.llocation ratio, considering an undeterminable primary end
oint in 10% of patients and an overall experimental type I
rror of 0.05 using a 2-sided hypothesis test. Discrete data
re summarized as frequencies, whereas continuous data are
ummarized as mean  SD or median and interquartile
ange (IQR) as appropriate. The chi-square test or Fisher
xact test was used for comparison of categorical variables,
nd the unpaired 2-tailed Student t test or Mann-Whitney
ank-sum test was used to test differences among continuous
ariables. Survival curves were generated using the Kaplan-
eier method, and the difference between groups was
ssessed by log-rank test. The multivariable analysis to
valuate the independent contribution of clinical, angio-
raphic, and procedural variables to the surrogate and
linical end points were performed by forward stepwise
ogistic regression analysis or the Cox proportional hazards
odel. For logistic regression analyses, model discrimina-
ion was assessed with c-statistic, and goodness of fit with
he Hosmer-Lemeshow test. All tests were 2-sided, and a
 0.05 was considered significant. All analyses were
erformed using the software package SPSS version 11.5
SPSS, Inc., Chicago, Illinois).
esults
tudy enrollment began in December 2005 and ended in
eptember 2009, and 501 patients from 8 sites were
andomly assigned to RT before DS or DS alone. The mean
ge of the entire patient cohort was 63.7  11.9 years, 38%
f patients had anterior AMI, and 4% of patients were in
ardiogenic shock due to left ventricular failure on admis-
ion. Thrombus grade 5 rate after coronary wiring was
8.4% in the RT arm and 24.3% in the direct stenting arm.
he 2 study arms were well matched in all baseline
haracteristics (Tables 1 and 2).
Table 3 summarizes the procedural characteristics. The
edian delay from hospital admission to artery puncture
ctomy Direct Stenting
(n  245) p Value
0.483
91 (37)
120 (49)
34 (14)
4) 2.91 (2.62–3.25) 0.670
95 (39) 0.192
5) 203/242 (83.9) 0.899
5) 129/222 (58.1) 0.465
0.640
3 (1.4)
80 (37.4)
79 (36.9)
52 (24.3)ics
rombe
256)
)
)
)
67–3.2
)
4 (83.
1 (61.
4)
.5)
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Rheolytic Thrombectomy October 12, 2010:1298–306as similar in the 2 arms: 34 min (IQR 15 to 67 min) in the
T arm and 31 min (IQR 18 to 60 min) in the DS arm.
ompliance with assigned treatments was high in both
rms: 88% of patients had DS, and 97% of patients received
bciximab. Nearly all patients (94%) in the thrombectomy
rm received the treatment without the need for target
esion pre-dilation, whereas only 2% of patients randomized
o DS alone crossed over to thrombectomy. Patients in the
S alone arm received more stents, with a resulting higher
otal stent length. The total procedural time (time from
rterial puncture to the completion of the final angiogram)
as longer in the RT arm (additional median procedural
ime 13.5 min).
No major procedural complications occurred in the RT
rm, whereas 1 patient in the DS alone arm had a coronary
erforation that was treated with a covered stent. Overall,
ajor bleeding complication rate was 2.8%, and was similar
etween the 2 groups.
urrogate End PointsTable 4 Surrogate End Points
Rheolytic
Thrombectomy Direct Stenting p Value
Early ST-segment resolution n 246 n 240
211 (85.8) 189 (78.8) 0.043
Infarct size n 217 n 208
11.8 (3.15–23.70) 12.75 (4.75–23.3) 0.398
TIMI flow grade 3 n 252 n 241
203 (80.6) 207 (85.9) 0.113
Corrected TIMI frame count n 228 n 216
20 (15–27.25) 20 (14–25.75) 0.357
TIMI blush grade n 215 n 211 0.207
Grade 0 7 (3.3) 2 (0.9)
Grade 1 10 (4.7) 9 (4.3)
Grade 2 43 (20.0) 33 (15.6)
Grade 3 155 (72.1) 167 (79.1)
Procedural CharacteristicsTable 3 Procedural Characteristics
Rheolytic Th
(n 
Emergency room to PCI, min* 34 (1
Procedural time, min 59.5 (4
Temporary pacemaker before RT 2 (0
Pre-dilation before RT 5/2
TIMI flow grade 3 after RT 159/2
Pre-dilation before stenting 25 (9
Stent per patient 1.26
Mean stent length, mm 23.7
Multiple stenting 58 (2
Abciximab 249 (9
Intra-aortic balloon pump 8 (3
Procedural success† 237 (9
Values are median (interquartile range), n (%), or mean  SD. *Time f
grade 3 by operator’s assessment.
DS  direct stenting; RT  rheolytic thrombectomy; other abbreviaalues are n (%) or median (interquartile range).
Abbreviation as in Table 2.
VTable 4 summarizes the surrogate end point results. Of
01 patients, 486 (97%) had paired electrocardiograms
vailable for ST-segment analysis. ST-segment elevation
esolution occurred in 85.8% of patients randomly assigned
o thrombectomy and in 78.8% of patients randomly allo-
ated to DS alone (p  0.043).
Of 501 patients, 415 (83%) had scintigraphy available for
easurement of infarct size. Infarct size was smaller in the
hrombectomy arm, but this difference did not reach statis-
ical significance: the median infarct size was 11.8% (IQR
linical End PointsTable 5 Clinical End Points
Rheolytic
Thrombectomy
(n  256)
Direct
Stenting
(n  245) p Value
1 month
MACE 8 (3.1) 17 (6.9) 0.050
Death 4 (1.6) 7 (2.9)
Myocardial infarction 2 (0.8) 3 (1.2)
TVR 2 (0.8) 6 (2.5)
Stroke 0 (0) 1 (0.4)
Major bleeding 10 (3.9) 4 (1.6) 0.123
Stent thrombosis 3 (1.2) 4 (1.6) 0.660
6 months n 251 n 242
MACE 28 (11.2) 47 (19.4) 0.011
Death 7 (2.8) 11 (4.5)
Myocardial infarction 2 (0.8) 3 (1.2)
TVR 18 (7.2) 32 (13.2)
Stroke 1 (0.4) 1 (0.4)
1 year* n 221 n 220
MACE 33 (14.9) 50 (22.7) 0.036
Death 7 (3.2) 14 (6.4)
Myocardial infarction 2 (0.9) 3 (1.4)
TVR 22 (9.9) 32 (14.5)
Stroke 2 (0.9) 1 (0.4)
ctomy Direct Stenting
(n  245) p Value
31 (18–60) 0.727
) 46 (35–60) 0.001
)
)
34 (13.9) 0.149
1.40 0.73 0.022
25.9 14.1 0.050
72 (30) 0.079
239 (98) 0.841
9 (3.7) 0.735
229 (93.5) 0.696
mission to arterial puncture. †Residual stenosis 30% and TIMI flow
in Tables 1 and 2.rombe
256)
5–67)
4.7–70
.7)
41 (2.1
22 (72
.8)
0.54
10.9
3)
7)
.1)
2.6)
rom adalues are n (%). *Eligible patients, n  452.
MACE  major adverse cardiovascular events; TVR  target vessel revascularization.
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October 12, 2010:1298–306 Rheolytic Thrombectomy.15% to 23.70%) in the thrombectomy arm and 12.7%
IQR 4.75% to 23.30%) in the DS alone arm (p  0.398).
With regard to the secondary angiographic surrogate
nd points, the number of patients who could be assessed
y the core laboratory for post-procedure TIMI flow
rade 3, corrected TIMI frame count, and TIMI myo-
ardial blush were 493 (98%), 444 (87%), and 426 (85%),
Figure 2 Clinical Outcome
Clinical outcome at (A) 1 month, (B) 6 months, and (C) 1 year rheolytic thrombec
MACE  major adverse cardiovascular events; MI  myocardial infarction; TVR espectively. None of these 3 angiographic end points was
ifferent between treatment arms. A myocardial blush
rade 3 was revealed in 70% of patients in both arms.
Table 5 and Figure 2 summarize the clinical outcome.
he 1-month MACE rate was 3.1% in the thrombectomy
rm and 6.9% in the DS alone arm (p  0.05). The
ifference between arms in MACE rate was increased at
RT [green bars]) versus direct stenting (DS [red bars]).
vessel revascularization.tomy (
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Rheolytic Thrombectomy October 12, 2010:1298–306-month follow-up (11.2% and 19.4%, respectively; p 
.011), and maintained at 1-year follow-up (14.9% and
2.7%, respectively; p  0.036). By Kaplan-Meier analysis,
he 1-year estimated freedom from MACE was 85.2 
.3% for the thrombectomy arm, and 75.0  3.1% for the
S alone arm (p  0.009) (Fig. 3). The STR was inversely
elated to the occurrence of 1- and 6-month MACE and
eath (Table 6).
Table 7 shows the multivariable analysis of predictors of
arly STR and MACE. Randomization to RT was associ-
ted both with STR (odds ratio: 1.70, 95% confidence
nterval: 1.03 to 2.82, p  0.039; c-statistic  0.72;
osmer-Lemeshow test p  0.460) and the occurrence of
-year MACE (hazard ratio: 0.55, 95% confidence interval:
.35 to 0.86, p  0.008).
iscussion
he 2 main findings of the present study can be summarized
s follows: 1) randomization to RT was associated with
100
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%
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Figure 3 Freedom From MACE
Kaplan-Meier estimate of freedom from major adverse cardiovascular events
(MACE), rheolytic thrombectomy (RT [red bars]) versus direct stenting (DS
[green bars]).
T-Segment Resolutionnd 6-Month Clinical OutcomeTable 6 ST-Segme t Resolutionand 6-Month Clinical Outcome
ST-Segment Resolution
(n  400)
Non–ST-Segment Resolution
(n  86) p Value
1 month
Death (%) 5 (1.3) 6 (7.0) 0.001
MACE (%) 15 (3.8) 10 (11.6) 0.003
6 months n 365 n 80
Death (%) 10 (2.7) 8 (10) 0.003
MACE (%) 53 (14.5) 22 (27.5) 0.005abbreviations as in Table 5.ore frequent STR than was DS alone, whereas no differ-
nce was found in the other surrogate markers of myocardial
eperfusion; and 2) RT plus DS as compared with DS alone
esulted in a significant decrease in MACE at 1 month, and
his difference was increased at 6 and 12 months.
The difference in STR between the 2 arms did not reach
he pre-defined  value of 0.025, which is the standard value
or a study including 2 coprimary end points. However, the
ignificance of the difference observed in this trial is sup-
orted by the results of the multivariable analysis that shows
andomization to RT to be an independent predictor both
f STR and MACE. Moreover, STR was strongly associ-
ted with the occurrence of death and MACE. These
nding confirms STR, as defined in our study, as a valid
urrogate end point, and further supports the significance of
he observed difference between arms.
Several explanations may be proposed as to why the study
id not show difference between arms in the other surrogate
nd points. Regarding infarct size, the most likely explana-
ion is the poor spatial resolution of 99mTc sestamibi
cintigraphy, about 10  10  10 mm full width half
aximum. Thus, it will miss differences smaller than this
ize especially in the extent of subendocardial infarction
15). With regard to the angiographic surrogate end points,
t should be noted that their assessment derives from a
ingle time point sampling of a dynamic phenomenon and
hat these snapshot measurements cannot fully explore the
ntegrity of the microvessel network (16). Finally, it should
e noted that in contrast to other trials of thrombectomy in
MI, the study assessed the potential additive value of
djunctive thrombectomy in patients receiving routine DS
ithout pre- or post-dilation and abciximab with an asso-
iated risk of embolization and microvessel disruption lower
han conventional balloon angioplasty followed by stenting
r nonuse of abciximab (17–20). As a result, in the control
redictors of EarlyT-Segment Resolution and MACCETable 7 Predictors of EarlyST-Segment Resolution and MACCE
Predictor Odds Ratio 95% CI p Value
Early ST-segment resolution
Rheolytic thrombectomy 1.70 1.03–2.82 0.039
Anterior AMI 0.29 0.17–0.47 0.001
Post-PCI TIMI flow grade 3 2.10 1.17–3.80 0.013
One-Month MACCE
Rheolytic thrombectomy 0.34 0.13–0.89 0.028
Post-PCI TIMI flow grade 3 0.17 0.07–0.42 0.001
Major bleeding 7.50 1.84–30.48 0.005
Hazard Ratio
1-year MACCE
Rheolytic thrombectomy 0.55 0.35–0.86 0.008
Age 1.03 1.01–1.05 0.004
Major bleeding 3.28 1.37–7.86 0.008
MI acute myocardial infarction; CI confidence interval; MACCEmajor adverse cardiac and
erebrovascular events; other abbreviations as in Tables 1 and 2.rm, myocardial perfusion as assessed by electrocardio-
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etter than expected.
The most important finding of the study is the better
linical outcome of patients randomized to RT plus DS as
ompared with DS alone. The RT was inversely related to
he risk of adverse events and was associated with a nearly
0% relative reduction in MACE. The difference between
rms was driven mainly by death and TVR, suggesting that
he benefit of thrombectomy is related both to better
yocardial reperfusion and to decreased recurrent ischemia.
he latter could be related to increased stent length and
ncomplete apposition in the control arm due to the pres-
nce of unresolved thrombus. This hypothesis is supported
y a nonrandomized study on RT on primary PCI per-
ormed by Sianos et al. (21) that has shown that a baseline
arge thrombus is a strong predictor of early and late stent
hrombosis, and that patients treated with RT before
tenting had a lower stent thrombosis and MACE rates
han patients treated with conventional PCI.
The safety profile of RT, as revealed in this study, is high,
onsidering that no major procedural complications related
o the device were encountered, and that 1% of patients
eeded a temporary pacemaker to prevent or treat severe
radycardia.
The results of the JETSTENT trial are not consistent
ith the results of the AIMI (Angiojet Rheolytic Throm-
ectomy In Patients Undergoing Primary Angioplasty for
cute Myocardial Infarction) trial (7). The AIMI trial,
hich enrolled 480 patients, did not show difference in STR
etween the thrombectomy arm and control, while infarct
ize as assessed by 99mTc sestamibi scintigraphy was larger
nd 1-month MACE rate was higher in the thrombectomy
rm. The difference in MACE rate was attributable to a
igher mortality in the thrombectomy arm as compared
ith control (4.6% and 0.8%, respectively; p  0.02).
hereas the JETSTENT trial included only patients with
ngiographic evidence of thrombus, the AIMI trial excluded
atients with large amounts of thrombus, and only a
inority of patients (21%) had evidence of moderate or
arge thrombus. Moreover, some procedural findings may
xplain the worse outcome in the AIMI trial, such as the use
f a retrograde technique in the majority of thrombectomy
atients that includes first crossing the lesion without the
evice activated, with the associated increased risk of em-
olism, the high delay from admission to randomization
2.5 h), and the high major procedural complication rate
10%). All these procedural findings with their negative
mpact on outcome may have overcome any benefit of
hrombectomy.
Two other studies have demonstrated a clinical benefit of
emoval of thrombus using manual aspiration catheters, the
APAS (Thrombus Aspiration During Percutaneous Cor-
nary Intervention in Acute Myocardial Infarction Study)
rial and the EXPIRA (Thrombectomy With Export Cath-
ter in Infarct-Related Artery During Primary Percutaneous
oronary Intervention) trial (22,23). Major differences intudy design and procedural characteristics prevent the
omparison of these studies to the JETSTENT trial.
owever, all 3 studies contribute to a growing body of
vidence confirming the benefit of thrombus removal before
nfarct artery stenting.
onclusions
lthough the primary efficacy end points were not met, the
esults of this study support the use of RT before infarct
rtery stenting in patients with AMI and evidence of
oronary thrombus. However, the routine use of RT in
MI should be confirmed by future larger trials.
eprint requests and correspondence: Dr. David Antoniucci,
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